InvestorLens

NAMS — NEWAMSTERDAM PHARMA COMPANY

Public company

Sign in to save5 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying NAMS?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
65
Institutional Conviction
Net distribution · 0 buying vs 0 selling last quarter
38
Macro Tailwind
Macro conditions are mixed for this sector
56
Why? — Evidence & Confidence ▾

No tracked investor changed their NAMS position last quarter. Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).

Supporting evidence
  • +5 tracked investors reported holding NAMS at their latest filing
  • +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About NEWAMSTERDAM PHARMA COMPANY (NAMS)

NEWAMSTERDAM PHARMA COMPANY (NAMS) appears in the most recent 13F filings of 5 tracked institutional investors. The largest disclosed position is held by Andreas Halvorsen (Viking Global Investors), valued at $184M. Across recent filings, tracked investors recorded 2 new positions, 4 increased, 3 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in NAMS

67
/100
Institutional Accumulation
Added / Increased6
Reduced3
Exited0
BearishBullish
Crowded Trade Score™

How many top investors track NAMS

33
/100
Emerging Interest
5investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

NAMS Ownership Composition

How NEWAMSTERDAM PHARMA COMPANY is held across tracked investor types, based on reported 13F positions.

Dominant Type
Other
49% of tracked value
Institutions
5
tracked investors
Total Reported
$293.7M
combined 13F value
Types3
  • Other48.5%
  • Macro35.4%
  • Multi-Strategy / Quant16.1%
Other(1)
48.5%
Macro(1)
35.4%
Multi-Strategy / Quant(3)
16.1%

Tracked investors currently reporting NAMS

1 tracked investor has since exited this position — listed separately below.

  • Andreas HalvorsenJun 30, 2026
    Viking Global Investors
    Shares
    4.2M
    Value
    $142.5M
    % Portfolio
    0.41%
  • Stanley DruckenmillerJun 30, 2026
    Duquesne Family Office
    Shares
    3.1M
    Value
    $104M
    % Portfolio
    2.00%
  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    684.2K
    Value
    $23.2M
    % Portfolio
    0.00%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    501.6K
    Value
    $17M
    % Portfolio
    0.01%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    205.5K
    Value
    $7M
    % Portfolio
    0.01%

Previously held NAMS

These investors reported NAMS in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Paul Tudor JonesTudor Investment Corp52.2K$1.3MDec 31, 2024

Recent activity

Frequently asked questions

How many institutional investors hold NAMS?
5 tracked institutional investors disclosed a position in NAMS (NEWAMSTERDAM PHARMA COMPANY) in their most recent 13F filing.
Who is the largest institutional holder of NAMS?
Andreas Halvorsen, Viking Global Investors, holds the largest disclosed position in NAMS, valued at $184M.
Did institutional ownership of NAMS increase or decrease?
Across recent 13F filings, tracked investors recorded 2 new positions, 4 increased, 3 reduced, and 0 fully exited NAMS.
Where does this NAMS ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
NAMS (NEWAMSTERDAM PHARMA COMPANY) — Institutional Holders — InvestorLens